Edesa Biotech Inc reports results for the quarter ended in September - Earnings Summary

Edesa Biotech

15/12/2023 22:20

* Edesa Biotech Inc  EDSA.OQ  reported a quarterly adjusted
loss
of 60 cents​​ per share for the quarter ended in September,
lower than the same quarter last year, when the company reported
EPS of -14 cents.  The mean expectation of three analysts for
the quarter was for a loss of 71 cents per share. Wall Street
expected results to range from -73 cents to -68 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Edesa Biotech Inc's reported EPS for the quarter was a
loss
of 60 cents​.
    * The company reported a quarterly loss of $1.72 million.
    * Edesa Biotech Inc shares had risen by 16.4% this
quarter and
lost 65.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.5%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Edesa Biotech Inc
is $30.00 
This summary was machine generated from LSEG data December 15 at
10:19 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.71          -0.60          Beat
 Jun. 30 2023      -1.21          -0.70          Beat
 Mar. 31 2023      -1.21          -0.84          Beat
 Dec. 31 2022      -1.33          -0.91          Beat